Table 8.

Treatment effects on serum PTH (pg/ml) in the Daily and Nocturnal Trials

TrialSessions per Week (n)Observed Patients with Complete Data 
(Median and 10th–90th Percentile Range)aAdjusted Geometric Mean % Change and Treatment Effects (95% CI)
Baseline3–5 Mo10–12 Mo3–5 Mo Adjusted Mean Change ± SEM3–5 Mo Treatment Effect
(95% CI)10–12 Mo Adjusted Mean Change ± SEM10–12 Mo Treatment Effect (95% CI)
Daily3282 (44, 846)265 (54, 751)258 (46, 832)1.5 (−13.7 to 19.4)7.5 (−13.2 to 33.2)−7.9 (−24.8 to 12.8)26.02b
(−3.4 to 64.2)
6326 (94, 859)350 (121, 1013)369 (118, 972)9.1 (−7.0 to 28.1)16.0 (−4.0 to 40.0)
Nocturnal3331 (112, 618)220 (22, 1268)268 (38, 1364)−32.0 (−51.6 to −4.4)0.3 (−37.5 to 61.0)−11.4 (−39.2 to 28.9)−38.23c
(−63.4 to 4.2)
6296 (77, 650)235 (25, 618)233 (13, 672)−31.8 (−51.1 to −4.8)−45.3 (−62.2 to −20.8)
  • a Results provided for patients with nonmissing serum PTH at baseline, month 4, and month 12.

  • b P=0.09.

  • c P=0.07.